Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313406908> ?p ?o ?g. }
Showing items 1 to 60 of
60
with 100 items per page.
- W4313406908 endingPage "126.38" @default.
- W4313406908 startingPage "126.38" @default.
- W4313406908 abstract "Abstract Epstein-Barr Virus (EBV) is a complex oncogenic γ-herpesvirus that infects around 90% of the global adult human population. Upon primary infection, EBV typically persists asymptomatically in form of a latent infection. However, under certain circumstances the virus can malignantly transform lymphocytes and epithelial cells leading to cancers such as Diffuse Large B Cell Lymphoma (DLBCL) and Stomach Adenocarcinoma (STAD) respectively. Unfortunately, it is difficult to target latent EBV using the current immuno-therapeutic strategies, specifically due to reduced antigen expression. Cytolytic Virus Activation (CLVA) therapy is an approach that can specifically target and kill tumor cells that harbor EBV in a lytic state. The switch from latent to lytic phase can be mediated by a plethora of chemical compounds or lytic inducers. Recently, in our lab, we have developed an intuitive in-silico drug prediction approach to rapidly screen and identify FDA-approved or clinically available compounds that can be repurposed to induce lytic cycle in different EBV+ tumors. Using this strategy, we identified a range of HDACi and Iron chelators as inducers of lytic cycle in EBV+ epithelial cancers. Interestingly, these drugs also significantly induced the expression of Programmed Death Ligand-1 (PD-L1) protein, a major target of Immune checkpoint blockade (ICB) therapy. This led us to hypothesize that by utilizing such an in-silico drug prediction approach, we can identify cancer specific drugs that are potent inducers of EBV lytic cycle. To better understand the underlying mechanisms, we are now investigating the effect of these cytolytic compounds in vivo using xenograft mouse models. Supported by SIRG Graduate Research Assistantship Award PCCR-SIRG-FY2022-01 (P30CA023168) from Purdue University" @default.
- W4313406908 created "2023-01-06" @default.
- W4313406908 creator A5029731301 @default.
- W4313406908 creator A5036588904 @default.
- W4313406908 creator A5069039075 @default.
- W4313406908 date "2022-05-01" @default.
- W4313406908 modified "2023-09-25" @default.
- W4313406908 title "Iron chelators and HDAC inhibitors are potent inducers of Epstein-Barr Virus Lytic cycle in Stomach Adenocarcinoma" @default.
- W4313406908 doi "https://doi.org/10.4049/jimmunol.208.supp.126.38" @default.
- W4313406908 hasPublicationYear "2022" @default.
- W4313406908 type Work @default.
- W4313406908 citedByCount "0" @default.
- W4313406908 crossrefType "journal-article" @default.
- W4313406908 hasAuthorship W4313406908A5029731301 @default.
- W4313406908 hasAuthorship W4313406908A5036588904 @default.
- W4313406908 hasAuthorship W4313406908A5069039075 @default.
- W4313406908 hasConcept C109316439 @default.
- W4313406908 hasConcept C159047783 @default.
- W4313406908 hasConcept C182615771 @default.
- W4313406908 hasConcept C202751555 @default.
- W4313406908 hasConcept C203014093 @default.
- W4313406908 hasConcept C2522874641 @default.
- W4313406908 hasConcept C2779338263 @default.
- W4313406908 hasConcept C2781375147 @default.
- W4313406908 hasConcept C502942594 @default.
- W4313406908 hasConcept C55493867 @default.
- W4313406908 hasConcept C73588182 @default.
- W4313406908 hasConcept C86803240 @default.
- W4313406908 hasConceptScore W4313406908C109316439 @default.
- W4313406908 hasConceptScore W4313406908C159047783 @default.
- W4313406908 hasConceptScore W4313406908C182615771 @default.
- W4313406908 hasConceptScore W4313406908C202751555 @default.
- W4313406908 hasConceptScore W4313406908C203014093 @default.
- W4313406908 hasConceptScore W4313406908C2522874641 @default.
- W4313406908 hasConceptScore W4313406908C2779338263 @default.
- W4313406908 hasConceptScore W4313406908C2781375147 @default.
- W4313406908 hasConceptScore W4313406908C502942594 @default.
- W4313406908 hasConceptScore W4313406908C55493867 @default.
- W4313406908 hasConceptScore W4313406908C73588182 @default.
- W4313406908 hasConceptScore W4313406908C86803240 @default.
- W4313406908 hasIssue "1_Supplement" @default.
- W4313406908 hasLocation W43134069081 @default.
- W4313406908 hasOpenAccess W4313406908 @default.
- W4313406908 hasPrimaryLocation W43134069081 @default.
- W4313406908 hasRelatedWork W1487857142 @default.
- W4313406908 hasRelatedWork W1984710154 @default.
- W4313406908 hasRelatedWork W2015616819 @default.
- W4313406908 hasRelatedWork W2018457864 @default.
- W4313406908 hasRelatedWork W2026608413 @default.
- W4313406908 hasRelatedWork W2100232224 @default.
- W4313406908 hasRelatedWork W2118087741 @default.
- W4313406908 hasRelatedWork W2121615812 @default.
- W4313406908 hasRelatedWork W2767420145 @default.
- W4313406908 hasRelatedWork W3175832157 @default.
- W4313406908 hasVolume "208" @default.
- W4313406908 isParatext "false" @default.
- W4313406908 isRetracted "false" @default.
- W4313406908 workType "article" @default.